Hemophilia Treatment Market Size & Share Report, 2032

Hemophilia Treatment Market – Disease Type (Hemophilia A, Hemophilia B), Product (Recombinant Factor Concentrates), Patient (Pediatric, Adult), Treatment (Prophylaxis, On Demand), Therapy, Drug Class, Route of Administration, End-use – Global Forecast 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp;Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp;Research design

1.2.1&nbsp;&nbsp;&nbsp;Research approach

1.2.2&nbsp;&nbsp;&nbsp;Data collection methods

1.3&nbsp;&nbsp;&nbsp;Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp;Base year calculation

1.3.2&nbsp;&nbsp;&nbsp;Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp;Forecast model

1.5&nbsp;&nbsp;&nbsp;Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp;Primary sources

1.5.2&nbsp;&nbsp;&nbsp;Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp;Industry 360° synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights 

3.1&nbsp;&nbsp;&nbsp;Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp;Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp;Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Growing prevalence of hemophilia across the globe

3.2.1.2&nbsp;&nbsp;&nbsp;Rise in favorable government initiatives

3.2.1.3&nbsp;&nbsp;&nbsp;Increase in R&amp;D and new product development

3.2.1.4&nbsp;&nbsp;&nbsp;Growing adoption of prophylaxis treatment

3.2.2&nbsp;&nbsp;&nbsp;Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost associated with hemophilia treatment

3.2.2.2&nbsp;&nbsp;&nbsp;Lack of awareness in developing and under-developed regions

3.2.2.3&nbsp;&nbsp;&nbsp;Low adoption rates of technologically advanced products

3.3&nbsp;&nbsp;&nbsp;Growth potential analysis

3.4&nbsp;&nbsp;&nbsp;Regulatory landscape

3.5&nbsp;&nbsp;&nbsp;Future market trends

3.6&nbsp;&nbsp;&nbsp;Pipeline analysis

3.7&nbsp;&nbsp;&nbsp;Porter&rsquo;s analysis

3.8&nbsp;&nbsp;&nbsp;PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp;Introduction

4.2&nbsp;&nbsp;&nbsp;Company market share analysis

4.3&nbsp;&nbsp;&nbsp;Company matrix analysis

4.4&nbsp;&nbsp;&nbsp;Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp;Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp;Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Type, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp;Key trends

5.2&nbsp;&nbsp;&nbsp;Hemophilia A

5.2.1&nbsp;&nbsp;&nbsp;Severe

5.2.2&nbsp;&nbsp;&nbsp;Moderate

5.2.3&nbsp;&nbsp;&nbsp;Mild

5.3&nbsp;&nbsp;&nbsp;Hemophilia B

5.3.1&nbsp;&nbsp;&nbsp;Severe

5.3.2&nbsp;&nbsp;&nbsp;Moderate

5.3.3&nbsp;&nbsp;&nbsp;Mild

5.4&nbsp;&nbsp;&nbsp;Other disease types

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp;Key trends

6.2&nbsp;&nbsp;&nbsp;Recombinant coagulation factor concentrates

6.2.1&nbsp;&nbsp;&nbsp;Factor VIII

6.2.2&nbsp;&nbsp;&nbsp;Factor IX

6.3&nbsp;&nbsp;&nbsp;Plasma-derived coagulation factor concentrates

6.3.1&nbsp;&nbsp;&nbsp;Factor VIII

6.3.2&nbsp;&nbsp;&nbsp;Factor IX

6.4&nbsp;&nbsp;&nbsp;Extended half-life products

6.4.1&nbsp;&nbsp;&nbsp;Factor VIII

6.4.2&nbsp;&nbsp;&nbsp;Factor IX

6.5&nbsp;&nbsp;&nbsp;Desmopressin

6.6&nbsp;&nbsp;&nbsp;Antifibrinolytic agents

6.7&nbsp;&nbsp;&nbsp;Gene therapy products

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Patient, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp;Key trends

7.2&nbsp;&nbsp;&nbsp;Pediatric

<ul>
	<li style="margin-left: 30pt;">7.2.1. 0to 4</li>
	<li style="margin-left: 30pt;">7.2.2. 5to 13</li>
	<li style="margin-left: 30pt;">7.2.3. 14to18</li>
</ul>

7.3&nbsp;&nbsp;&nbsp;Adult

<ul>
	<li style="margin-left: 30pt;">7.3.1. 19to 44</li>
	<li style="margin-left: 30pt;">.7.3.2. 45+&nbsp;&nbsp;&nbsp;</li>
</ul>

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp;Key trends

8.2&nbsp;&nbsp;&nbsp;Prophylaxis

8.3&nbsp;&nbsp;&nbsp;On demand

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapy, 2021 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp;Key trends

9.2&nbsp;&nbsp;&nbsp;Factor replacement therapy

9.3&nbsp;&nbsp;&nbsp;Non-factor replacement therapy

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Drug Class, 2021 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp;Key trends

10.2&nbsp;&nbsp;&nbsp;Vasopressin

10.3&nbsp;&nbsp;&nbsp;Coagulation factors

Chapter 11&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2021 &ndash; 2032 ($ Mn)

11.1&nbsp;&nbsp;&nbsp;Key trends

11.2&nbsp;&nbsp;&nbsp;Injectable

11.3&nbsp;&nbsp;&nbsp;Nasal spray

11.4&nbsp;&nbsp;&nbsp;Oral

Chapter 12&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-use, 2021 &ndash; 2032 ($ Mn)

12.1&nbsp;&nbsp;&nbsp;Key trends

12.2&nbsp;&nbsp;&nbsp;Hospitals

12.3&nbsp;&nbsp;&nbsp;Clinics

12.4&nbsp;&nbsp;&nbsp;Hemophilia treatment centers

12.5&nbsp;&nbsp;&nbsp;Other end-users

Chapter 13&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

13.1&nbsp;&nbsp;&nbsp;Key trends

13.2&nbsp;&nbsp;&nbsp;North America

13.2.1&nbsp;&nbsp;&nbsp;U.S.

13.2.2&nbsp;&nbsp;&nbsp;Canada

13.3&nbsp;&nbsp;&nbsp;Europe

13.3.1&nbsp;&nbsp;&nbsp;Germany

13.3.2&nbsp;&nbsp;&nbsp;UK

13.3.3&nbsp;&nbsp;&nbsp;France

13.3.4&nbsp;&nbsp;&nbsp;Spain

13.3.5&nbsp;&nbsp;&nbsp;Italy

13.3.6&nbsp;&nbsp;&nbsp;Netherlands

13.3.7&nbsp;&nbsp;&nbsp;Rest of Europe

13.4&nbsp;&nbsp;&nbsp;Asia Pacific

13.4.1&nbsp;&nbsp;&nbsp;China

13.4.2&nbsp;&nbsp;&nbsp;Japan

13.4.3&nbsp;&nbsp;&nbsp;India

13.4.4&nbsp;&nbsp;&nbsp;Australia

13.4.5&nbsp;&nbsp;&nbsp;South Korea

13.4.6&nbsp;&nbsp;&nbsp;Rest of Asia Pacific

13.5&nbsp;&nbsp;&nbsp;Latin America

13.5.1&nbsp;&nbsp;&nbsp;Brazil

13.5.2&nbsp;&nbsp;&nbsp;Mexico

13.5.3&nbsp;&nbsp;&nbsp;Rest of Latin America

13.6&nbsp;&nbsp;&nbsp;Middle East and Africa

13.6.1&nbsp;&nbsp;&nbsp;South Africa

13.6.2&nbsp;&nbsp;&nbsp;Saudi Arabia

13.6.3&nbsp;&nbsp;&nbsp;UAE

13.6.4&nbsp;&nbsp;&nbsp;Rest of Middle East and Africa

Chapter 14&nbsp;&nbsp;&nbsp;Company Profiles 

14.1&nbsp;&nbsp;&nbsp; Bayer AG

14.2&nbsp;&nbsp;&nbsp; Biogen Inc.

14.3&nbsp;&nbsp;&nbsp; Biotest AG (Grifols, S.A.)

14.4&nbsp;&nbsp;&nbsp; BioMarin Pharmaceutical Inc

14.5&nbsp;&nbsp;&nbsp; CSL Behring LLC

14.6&nbsp;&nbsp;&nbsp; Ferring B.V.

14.7&nbsp;&nbsp;&nbsp; Genentech, Inc. (Roche Holding AG)

14.8&nbsp;&nbsp;&nbsp; Kedrion S.p.A

14.9&nbsp;&nbsp;&nbsp; Novo Nordisk A/S

14.10&nbsp;&nbsp;&nbsp; Octapharma AG

14.11&nbsp;&nbsp;&nbsp; Pfizer, Inc.

14.12&nbsp;&nbsp;&nbsp; Sanofi SA

14.13&nbsp;&nbsp;&nbsp; Swedish Orphan Biovitrum AB

14.14&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Limited

&nbsp;&nbsp;

Hemophilia Treatment Market

Inquiry Before Buying

Industries

Information

Link

Global Headquarters